San Antonio Breast Cancer Symposium 2019: Importance of the CDK4/6-Inhibitor Abemaciclib in metastatic HR+, HER2-Breast Cancer strengthened

首页> 外文期刊>Oncology research and treatment. >San Antonio Breast Cancer Symposium 2019: Importance of the CDK4/6-Inhibitor Abemaciclib in metastatic HR+, HER2-Breast Cancer strengthened

【24h】

San Antonio Breast Cancer Symposium 2019: Importance of the CDK4/6-Inhibitor Abemaciclib in metastatic HR+, HER2-Breast Cancer strengthened

机译：San Antonio乳腺癌癌症研讨会：CDK4 / 6抑制剂的重要性在转移性HR +中，HER2-乳腺癌加强

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2020年第3期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. San Antonio Breast Cancer Symposium 2019: Importance of the CDK4/6-Inhibitor Abemaciclib in metastatic HR+, HER2-Breast Cancer strengthened [J] . Oncology research and treatment. . 2020,第3期

机译：San Antonio乳腺癌癌症研讨会：CDK4 / 6抑制剂的重要性在转移性HR +中，HER2-乳腺癌加强
2. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2(+) Metastatic Breast Cancer (vol 23, pg 5218, 2017) [J] . Dickler M. N., Tolaney S. M., Rugo H. S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第21期

机译：Monarch 1，难治性HR + / HER2（+）转移性乳腺癌患者（Vol 23，PG 5218,2017）中，乳房1，作为单一剂，作为单一药剂的ABEMAciclib，CDK4和CDK6抑制剂作为单一药剂的研究
3. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2(-) Metastatic Breast Cancer [J] . Dickler Maura N., Tolaney Sara M., Rugo Hope S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第17期

机译：Monarch 1，II期难治性HR + / HER2（ - ）转移性乳腺癌患者中的ABEMACIB，CDK4和CDK6抑制剂，作为单一剂，作为单一药剂
4. Correlation Between Glycan Biomarkers of Human Breast Cancer and a Mouse Model of Metastatic Breast Cancer [C] . Maria Lorna A. de Leoz, Lawrence J. T. Young, Hyun Joo An, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：人乳腺癌甘油生物标志物与转移性乳腺癌小鼠模型的相关性
5. The Impact of the "American Society of Breast Surgeons 2019 Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer" on Cancer Genetic Counselors [D] . ?Tokarczyk, Jillian 2020

机译：“美国乳房外科医生2019年围攻指南对遗传乳腺癌遗传检测”的影响癌症遗传咨询师
6. MONARCH 1 a phase 2 study of abemaciclib a CDK4 and CDK6 inhibitor as a single agent in patients with refractory HR+/HER2− metastatic breast cancer [O] . Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, -1

机译：MONARCH 1CDB4和CDK6抑制剂abemaciclib作为单一药物的2期研究用于难治性HR + / HER2-转移性乳腺癌患者
7. Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer [O] . 2018

机译：矫正：墨西哥乳酸，CDK4和CDK6抑制剂的II期研究，难治性HR + / HER2-转移性乳腺癌的患者
8. Novel Differentiation Therapy Approach to Reduce the Metastatic Potential of Basal, Highly Metastatic, Triple-Negative Breast Cancers. [R] . Chu, I. 2012

机译：新型分化治疗方法降低基底，高转移性，三阴性乳腺癌的转移潜能。

San Antonio Breast Cancer Symposium 2019: Importance of the CDK4/6-Inhibitor Abemaciclib in metastatic HR+, HER2-Breast Cancer strengthened

著录项

相似文献

相关主题

期刊订阅